title: [Anticancer drugs: Which prices for therapeutic innovations?].
abstract: The expanding knowledge of the biological mechanisms underlying tumor development made it possible the recent emergence of new therapeutic approaches that are considered as undoubtedly innovative. Yet, to define and to evaluate the magnitude of a drug innovation require an examination of its intrinsic drug properties, medical utility as well as its mode of emergence. Recently, international academic societies, such as ESMO and ASCO, have proposed practical tools that may help quantifying the medical value of a given innovation. Currently, the sustained flux of therapeutic innovations in oncology is associated with an unprecedented growth of costs, the actual determinants of which remain under debate, but raising the critical issue of drugs pricing, and their potential individual or societal "financial toxicity".
authors.affiliation: Institut Paoli-Calmettes, département d'oncologie médicale, 13009 Marseille, France; Centre de recherche en cancérologie de Marseille (institut Paoli-Calmettes, Inserm 1068, CNRS 7258, Aix-Marseille université), 13009 Marseille, France; Aix-Marseille université, 13284 Marseille, France. Electronic address: goncalvesa@ipc.unicancer.fr.
authors.forename: Anthony
authors.initials: A
authors.lastname: Gonçalves
authors.affiliation: Institut Paoli-Calmettes, département d'oncologie médicale, 13009 Marseille, France; Centre de recherche en cancérologie de Marseille (institut Paoli-Calmettes, Inserm 1068, CNRS 7258, Aix-Marseille université), 13009 Marseille, France; Aix-Marseille université, 13284 Marseille, France.
authors.forename: Dominique
authors.initials: D
authors.lastname: Maraninchi
authors.affiliation: Aix-Marseille université, 13284 Marseille, France; Institut Paoli-Calmettes, Inserm UMR912 SESSTIM, 13009 Marseille, France.
authors.forename: Patricia
authors.initials: P
authors.lastname: Marino
mesh_terms: D000970:Antineoplastic Agents / Q000191:economics*; D003362:Cost-Benefit Analysis; D004059:Diffusion of Innovation; D016527:Drug Costs; D005602:France; D017048:Health Care Costs / Q000639:trends; D006801:Humans; D058990:Molecular Targeted Therapy / Q000191:economics / Q000639:trends; D009369:Neoplasms / Q000175:diagnosis / Q000188:drug therapy* / Q000209:etiology; D012955:Societies, Medical
chemical_list: D000970:Antineoplastic Agents
keywords: Drug price; Financial toxicity; Immunotherapy; Immunothérapie; Innovations thérapeutiques; Médecine de précision; Precision medicine; Prix des médicaments; Targeted therapies; Therapeutic innovations; Thérapies ciblées; Toxicité financière